logo-loader

Anteris Technologies has valve world talking about 'human-like characteristics' of DurAVR

Published: 11:31 28 Sep 2022 AEST

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive about its productive presentation at the annual Transcatheter Cardiovascular Therapeutics (TCT) medical conference, the world’s largest interventional cardiology conference. 30-Day clinical data was presented for its full cohort of 13 patients implanted with DurAVR™ THV during its First-In-Human trial. It compared the results with outcomes of its most recent 22 patient study, which showed DurAVR™ THV technology performed favourably against other transcatheter aortic valve replacements and surgical aortic valve replacements at six months.

Anteris talks market superiority of its biomimetic TAVR valve

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive after the successful completion of enrolment for the company’s early feasibility study (EFS) to evaluate DurAVR™ THV. This unique device represents a new class of biomimetic valve and stands as the world's...

on 31/10/23